Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D
Hutchings et al., Endocrine, doi:/10.1007/s12020-020-02597-7
Hutchings et al., Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D, Endocrine, doi:/10.1007/s12020-020-02597-7
Jan 2021   Source   PDF  
  All Studies   Meta
Retrospective 330 hospitalized COVID-19 patients in Armenia, showing significantly higher prevalence of vitamin D deficiency (<12ng/mL) compared to health controls (45% vs. 13%).
Hutchings et al., 16 Jan 2021, retrospective, Armenia, peer-reviewed, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Endocrine (2021) 71:267–269 RESEARCH LETTER Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D Nicholas Hutchings 1,2 Varta Babalyan2 Sisak Baghdasaryan2 Mushegh Qefoyan2 Narina Sargsyants3 Elena Aghajanova4 Anna Martirosyan5 Ruzanna Harutyunyan5 Olga Lesnyak6 Anna Maria Formenti7 Andrea Giustina7 John P. Bilezikian2,8 ● ● ● ● ● ● ● ● ● ● ● 1234567890();,: 1234567890();,: Received: 24 November 2020 / Accepted: 17 December 2020 / Published online: 16 January 2021 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 The coronavirus (SARS-CoV-2) causes COVID-19. The disease has already afflicted over 54 million persons worldwide and has caused over 1.3 million deaths [1]. While most patients recovery uneventfully, some develop an acute pulmonary syndrome that requires hospitalization for supportive care [2]. Risk factors for symptomatic manifestations include male sex, diabetes mellitus, obesity, and hypertension [3, 4]. Another recently recognized potential risk factor is vitamin D deficiency. Vitamin D is an important modulator of innate and acquired immunity [5, 6]. Low levels are associated with bacterial and viral infections [7]. In addition, in countries with lower mean levels of 25-hydroxyvitamin D, mortality from COVID-19 is higher [8]. Preliminary studies suggest that vitamin D supplementation may improve outcomes [9]. While much of the data implicating vitamin D and COVID-19 has been indirect, recent reports have shown markedly reduced levels of 25-hydroxyvitamin D among those hospitalized with COVID-19 [10, 11]. These observations are consistent with * Nicholas Hutchings 1 School of Medicine, University of California, Irvine, CA, USA 2 Osteoporosis Center of Armenia, Yerevan, Armenia 3 Ministry of Health, Yerevan, Armenia 4 Muratsan University Hospital, Yerevan, Armenia 5 Saint Gregory the Illuminator Medical Center, Yerevan, Armenia 6 North West State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia 7 Institute of Endocrine and Metabolic Sciences, San Raffaele, Vita-Salute University and IRCCS Hospital, Milano, Italy 8 Endocrinology Division, Department of Medicine, New YorkPresbyterian Hospital / Columbia University Irving Medical Center, New York, NY, USA a plausible pathophysiological role of vitamin D in the disease process [6]. With an ethnically and culturally homogeneous population of approximately 3 million [12], Armenia has seen ~116,000 cases and 1700 deaths as of November 2020 [13]. At the Saint Gregory the Illuminator Medical Center (SGIMC) in Yerevan, a designated COVID-19 treatment hospital, we measured levels of 25-hydroxyvitamin D. We compared these levels with values that we have recently characterized in the free-living, healthy population of Armenia [14]. Methods Blood samples for measurement of 25-hydroxyvitamin D (ElectroChemiLuminescence immunoassay: Cobas e 411 autoanalyzer- Roche; Basel, Switzerland) were obtained from 330 consecutive hospitalized patients. We also recorded age, gender, height, weight, occupation, chronic conditions, prior tuberculosis infection, smoking status, use of supplemental oxygen, intubation status, duration of hospitalization until discharge, or death. Results Samples were collected over 5 weeks in summer, 2020. The most common comorbidities were hypertension,..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop